Press Archives
The George Washington University School of Medicine and Health Sciences researchers have been awarded a $3.6 million contract to genetically modify commensal organisms to produce antidotes for harmful biological and chemical agents, such as anthrax, Ebola, and even COVID-19.
The George Washington University (GW) School of Medicine and Health Sciences (SMHS) was recently awarded a T32 Ruth L. Kirschstein National Research Service Award institutional research training grant from the Health Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human Services focused on health care for individuals who are geographically isolated and/or economically or medically vulnerable.
This content is a press release from the Wolters Kluwer web site: Wolters Kluwer launches telemedicine resources to help clinicians provide virtual care | Wol
The GW Medical Faculty Associates will pilot a real-time remote monitoring tool for maternal mental health with Babyscripts, the leading virtual care platform for managing obstetrics. GW will be gathering data around the efficacy of the new tool for a focused research study.
GW researchers found low dose aspirin may reduce the need for mechanical ventilation, ICU admission and in-hospital mortality in hospitalized COVID-19 patients. Final results indicating the lung protective effects of aspirin were published today in Anesthesia & Analgesia.
The George Washington University announced today its participation in a Sanofi COVID-19 vaccine clinical trial. GW was selected as one of approximately 25 sites in the United States to launch a phase 2 study for its adjuvanted recombinant protein-based COVID-19 vaccine candidate.
Researchers at the George Washington University found that the majority of dermatology patients were comfortable with virtual visits as an alternative to in-person appointments.
While COVID-19 infected patients should be treated with standard anticoagulation therapies, such as blood thinning medication, a new study by researchers at the George Washington University shows that anticoagulating patients at higher doses, without traditional medical indications to do so, may be ineffective and even harmful.
